$Complete Response of Primary Refractory ALK-Positive Large B-Cell Lymphoma Treated With Single-Agent Nivolumab$

Complete Response of Primary Refractory ALK-Positive Large B-Cell Lymphoma Treated With Single-Agent Nivolumab

... Here we report a case of relapsed/refractory (R/R) ALK-positive LBCL with a prolonged complete response to single-agent nivolumab... Case Report: Here we report a case of relapsed/refractory (R/R) ALK-positive LBCL with a prolonged complete response to single-agent nivolumab... Conclusion: This is to our knowledge the first report of a complete response in a patient with primary refractory ALK-positive LBCL after treatment with nivolumab. Although recent reports showing low single-agent activity of checkpoint inhibitors in R/R DLBCL have been disappointing, patients with disease exhibiting exceptional response to immunotherapy are still seen and need to be further characterized. New cellular therapies may prove to be effective in these uncommon and aggressive lymphomas... READ ARTICLE

Clinical Lymphoma Myeloma and Leukemia DOI:10.1016/j.clml.2019.08.015

Authors: Jose D. Sandoval-Sus, Amanda Brahim, Alina Khan, Yehuda Deutsch, Barbara Raphael, Ali Ansari-Lari, Hugo F. Fernandez, Luis E. Raez

Case StudyKirk SmithMarch 1, 2020ALK-Positive, Large B-Cell Lymphoma, Nivolumab

Rapid Postoperative Relapse in ALK-Positive Locally Advanced NSCLC Patient with Complete Pathological Response to Neoadjuvant Crizotinib

In the April 2019 issue of the Journal of Thoracic Oncology, we reported cases of ALK-positive locally advanced NSCLC from two institutions in which neoadjuvant crizotinib showed quite acceptable efficacy and tolerability.1
Herein, we further describe the pathological evaluation and dynamic detection of circulating tumor DNA (ctDNA) in one patient receiving neoadjuvant crizotinib. Figure 1 summarizes the details of the entire therapeutic process. The patient is a 34-year-old male patient in whom lung adenocarcinoma and metastatic mediastinal lymph nodes were diagnosed and who received neoadjuvant crizotinib for 2 months. READ ARTICLE

Journal of Thoracic Oncology DOI:10.1016/j.jtho.2019.05.036

Authors: Chao Zhang, Yi-Long Wu, Wen-Zhao Zhong

ALK-Positive Lung Adenocarcinoma Arising in an Adolescent Treated for Relapsed Neuroblastoma

Pediatric lung adenocarcinoma is rare, but has been reported in patients with nonpulmonary childhood cancers.1, 2, 3 We report a case of a 17-year-old male who developed pulmonary adenocarcinoma with ALK receptor tyrosine kinase (ALK) rearrangement following neuroblastoma therapy. READ ARTICLE

Journal of Thoracic Oncology DOI:10.1016/j.jtho.2019.02.010

Authors: Yazeed Alwelaie, Rebecca J. Deyell, Helen R. Nadel, Tracy Tucker, Janessa Laskin, S. Rod Rassekh, Chen Zhou, John C. English, Anna F. Lee